A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

ClinicalTrials.gov ID: NCT02391259

Public ClinicalTrials.gov record NCT02391259. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Multicenter, Double-Blind, Placebo-Controlled, Rising Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, randomized, double-blind, placebo-controlled, sequential rising single-dose study in which approximately 56 subjects with SLE will be enrolled in 7 dosing cohorts

Study identification

NCT ID: NCT02391259
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Amgen; Industry
Enrollment: 57 participants

Conditions and interventions

Conditions

Systemic Lupus Erythematosus

Interventions

AMG 557 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2006 (Type not available)
Primary completion: Sep 2011 (Actual)
Completion: Nov 2011 (Actual)
Last update posted: Mar 30, 2015

2006 – 2011

United States locations

U.S. sites: 12
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Research Site	Anniston	Alabama	36207	—
Research Site	Phoenix	Arizona	85013	—
Research Site	Los Angeles	California	90033	—
Research Site	Los Angeles	California	90048	—
Research Site	Michigan City	Indiana	46360	—
Research Site	North Dartmouth	Massachusetts	02747	—
Research Site	Manhasset	New York	11030	—
Research Site	New York	New York	10003	—
Research Site	Rochester	New York	14642	—
Research Site	Duncansville	Pennsylvania	16635	—
Research Site	Dallas	Texas	75231	—
Research Site	Dallas	Texas	75247	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02391259, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 30, 2015 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02391259 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →